Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors in ADHF During Ventilator Weaning
NCT06142474Phase 3Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of empagliflozin and dapagliflozin in heart failure (HF) (3 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Composite of weaning failure, recurrent pulmonary edema, and cardiovascular/non-cardiovascular mortality at 90 days. Started Oct 2022; status: recruiting.
02
Drugs
empagliflozindapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06142474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142474.